Table 1 Patient demographics and baseline characteristics (full analysis set)
| Â | Placebo | Empagliflozin 10Â mg | Empagliflozin 25Â mg |
|---|---|---|---|
N | 21 | 20 | 19 |
Male | 17 (81.0) | 14 (70.0) | 16 (84.2) |
Age (years) | 60.7 (10.8) | 64.8 (5.9) | 62.6 (7.8) |
Time since diagnosis of type 2 diabetes | Â | Â | Â |
 ≤5 years | 9 (42.9) | 4 (20.0) | 5 (26.3) |
 >5 to 10 years | 9 (42.9) | 8 (40.0) | 7 (36.8) |
 >10 years | 3 (14.3) | 8 (40.0) | 7 (36.8) |
Number of anti-diabetes medications | Â | Â | Â |
 0 | 18 (85.7) | 16 (80.0) | 17 (89.5) |
 1 | 3 (14.3) | 4 (20.0) | 2 (10.5) |
Body weight (kg) | 67.7 (10.0) | 63.5 (10.6) | 65.9 (12.1) |
Body mass index (kg/m2) | 24.9 (2.8) | 24.1 (3.7) | 24.0 (3.2) |
HbA1c (%) | 8.00 (0.82) | 7.99 (0.83) | 7.73 (0.75) |
Fasting plasma glucose (mg/dl)* | 154.5 (19.8) | 151.0 (21.6) | 151.9 (23.3) |
AUC1-4 h for postprandial glucose (mg · h/dl) | 682.8 (91.2) | 680.4 (92.2) | 658.1 (116.2) |
24-hour mean glucose (mg/dl) | 184.1 (30.5) | 181.3 (25.9) | 178.4 (33.4) |
Mean amplitude of glucose excursions, MAGE (mg/dl) | 91.4 (26.4) | 94.1 (18.5) | 89.1 (29.7) |
Estimated glomerular filtration rate (ml/min/1.73Â m2) (Japanese estimation equation [27]) | 82.6 (12.8) | 76.5 (11.1) | 80.7 (9.3) |
Systolic blood pressure (mmHg)* | 119.8 (11.5) | 119.1 (15.9) | 124.0 (11.6) |
Diastolic blood pressure (mmHg)* | 71.8 (7.7) | 70.7 (10.7) | 74.7 (8.0) |